AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Optomed Oyj

Board/Management Information Sep 9, 2025

3329_rns_2025-09-09_73b81ef7-cbe2-4d8f-bad1-4ce58a41310b.html

Board/Management Information

Open in Viewer

Opens in native device viewer

Composition of Optomed's Nomination Board

Composition of Optomed's Nomination Board

Optomed PlcStock Exchange Release9 September 2025 at 9.30, Helsinki

Composition of Optomed's Nomination Board

According to Optomed's shareholder register of 1st of September 2025, the
shareholders represented in the shareholders' Nomination Board are OP
-Rahastoyhtiö Oy (OP funds),SP-Rahastoyhtiö Oy (SP Funds) and Danske Invest
Rahastoyhtiö Oy (Danske Funds). These shareholders have appointed the following
persons to the Nomination Board:

· Vesa Vanha-Honko, OP funds
· Petteri Vaarnanen, SP funds
· Ville Kivipelto, Danske Funds

Petri Salonen, Chairman of Optomed's Board of Directors, will serve as the
Nomination Board's expert member.
According to the resolution of Optomed General Meeting, the Optomed Nomination
Board consists of the representatives of Optomed three largest shareholders as
of the first trading day September, and the Chairman of the Board of Directors
as an expert member. Should a shareholder not wish to exercise the nomination
right, the right shall be transferred to the next largest shareholder who
otherwise would not be entitled to nominate a member.
The Nomination Board is to prepare proposals on the composition and members of
the Board of Directors and their remuneration for the next Annual General
Meeting and it will submit its proposal to the Board of Directors 31 January
2026 at the latest.

Optomed Plc

Further enquiries

Petri Salonen, Chairman of the Board, Optomed Plc, [email protected]

Optomed in Brief

Optomed is a Finnish medical technology company and one of the leading providers
of handheld fundus cameras. Optomed combines handheld cameras with software and
artificial intelligence with the aim to transform the diagnostic process of
blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its
business Optomed focuses on eye-screening devices and software solutions related
R&D in Finland and sales through different channels in over 60 countries.

www.optomed.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.